A Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 in HIV-1 Infected Antiretroviral Therapy Experienced Adults With Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance.

Trial Profile

A Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 in HIV-1 Infected Antiretroviral Therapy Experienced Adults With Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Fosdevirine (Primary) ; Darunavir; Etravirine; Raltegravir; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms SONNET
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 24 Oct 2013 Results reporting the incidence of new-onset seizures which subsequently led to trial discontinuation published in Antiviral Therapy.
    • 02 Nov 2010 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top